SCHEMBL23178591

SCHEMBL23178591

Nc1c(Cl)ccc(F)c1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
TSHR P16473 4/20 0.45
MAPK1 P28482 1/20 0.41
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
TP53 P04637 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
XBP1 P17861 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TLR9 Q9NR96 1/20 0.40
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18341031 0.85 ALDH1A1 (0.45) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL31569244 0.85 ALDH1A1 (0.45) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL11881928 0.84 ALDH1A1 (0.48) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL3756443 0.80 ALDH1A1 (0.42) ALDH1A1TSHRMAPTSMN1; SMN2TDP1
SCHEMBL29804997 0.80 TSHR (0.54) ALDH1A1TSHRMAPK1HTTMAPT
SCHEMBL3537340 0.80 TSHR (0.54) ALDH1A1TSHRMAPK1HTTMAPT
SCHEMBL11303709 0.80 ALDH1A1 (0.48) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL15347823 0.78 TDP1 (0.47) ALDH1A1TSHRMAPK1MAPTTDP1
SCHEMBL21248800 0.77 ALDH1A1 (0.45) ALDH1A1TSHRLMNAMAPTSMN1; SMN2
SCHEMBL102206 0.77 TSHR (0.45) ALDH1A1TSHRMAPK1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-23 US disclosed
CN-118974035-A 2-Aminoimidazole derivatives as PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-11-15 CN disclosed
EP-4426690-A2 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-09-11 EP disclosed
CN-112574176-B Heteroaryl compound and application thereof 隆泰申医药科技(南京) 有限公司 2024-03-15 CN disclosed
WO-2023081367-A2 2-AMINO IMIDAZOLE DERIVATIVES Mirati Therapeutics, Inc. (US) 2023-05-11 WO disclosed
WO-2021057696-A1 HETEROARYL COMPOUND AND APPLICATION THEREOF 隆泰申医药科技(南京)有限公司 2021-04-01 WO disclosed
WO-2021057696-A1 HETEROARYL COMPOUND AND APPLICATION THEREOF 隆泰申医药科技(南京)有限公司 2021-04-01 WO disclosed
CN-112574176-A Heteroaryl compound and application thereof 隆泰申医药科技(南京) 有限公司 2021-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 ALDH1A1 4159/4885TSHR 1646/4885MAPK1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.